Novartis, CH0012005267

Novartis stock trades at EUR 133.67 in weekend trading

Published on 10/18/2026 at 17:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock trades at EUR 133.67 in weekend trading on October 18, 2026. Novartis received FDA approval for Rhapsido on October 7, 2026.

FDA decision and trading status

Novartis reported FDA approval for Rhapsido on October 7, 2026.
Novartis stock trades in weekend trading at Lang & Schwarz at EUR 133.67 at 5:12 p.m. CEST on October 18, 2026.
The next Xetra session is scheduled for October 19, 2026.

Börsenanzeigetafel mit Candlestick-Charts und Händlern auf einem Schweizer Handelsparkett — Novartis AG CH0012005267 – Börsentafel mit Pharmacharts und Händlern auf belebtem Schweizer Trading-Floor, Illustration mit AI erstellt.

Novartis stock trades in weekend trading at Lang & Schwarz at EUR 133.67 at 5:12 p.m. CEST on October 18, 2026. The next Xetra session is October 19, 2026. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.

Market context: Market report SMI.

Company development

Novartis reported on October 7, 2026, that Rhapsido, or remibrutinib, received approval from the U.S. Food and Drug Administration as the first treatment for symptomatic dermographism. The company said the approval expands the medicine's use beyond chronic spontaneous urticaria. Novartis listed the announcement in its newsroom.